News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2011

SAVE THE DATE: Epigenomics – launch briefing on Epi proColon® 2.0 CE

20.10.2011 | 111020_Save_the_date_english Media briefing to take place at UEGW, Stockholm, Sweden, 25th October 2011 Berlin, Germany, and Seattle, WA, USA

Read more

Epigenomics AG reports Epi proColon® 2.0 finds 95% of cancers in clinical study

19.09.2011 | 110919_Epigenomics_AG_Press_release_Case_Control_Data Study provides clinical evidence for CE-marking in Europe and paves way to US pivotal clinical trial for submission to FDA before year-end Berlin, Germany, and Seattle, WA, USA Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today reported positive results in a clinical study for the Company’s second generation […]

Read more

Epigenomics AG Presents Mid-Year Results and Announces Restructuring Plan Heightening Focus on the Key U.S. Market

10.08.2011 | 110805_PR_H1_Results_EN_final Focus to be on near term product opportunities and key markets; streamlining of operations

Read more

Epigenomics AG Announces Restructuring of U.S. and European Operations

PDF 86 KB   Berlin, Germany, and Seattle, WA, U.S.A., August 10, 2011 Epigenomics AG (ISIN: DE000A1K0516) today released plans to restructure its organization and heighten the focus of its activities on the key U.S. market. Operations at the Epigenomics AG headquarters in Berlin, Germany, as well as at its subsidiary Epigenomics Inc. in Seattle, […]

Read more

Epigenomics AG: Surveys Show That Patients Believe in Blood Tests for Regular Colorectal Cancer Screening

07.07.2011 | 110707_PR_Surveys_EN_final Results of a joint survey by Epigenomics AG and europacolon during the first European Colorectal Cancer Patient Conference; nationwide survey in the U.S. reports similar results. 

Read more

Epigenomics AG: General Assembly Approves all Proposals including Reduction of Share Capital with vast majority

PDF 71 KB   Berlin, Germany, June 28, 2011 – Epigenomics AG‘s (ISIN: DE000A0BVT96) General Assembly today approved all decision proposals by the management with vast majority. The proposal to reduce the share capital and to consolidate of the shares at a ratio of 5:1 was approved with more than 99.8 % of the present […]

Read more